Last reviewed · How we verify
Leflunomide 10 milligram (MG)
Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby suppressing T-cell and B-cell proliferation.
Leflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby suppressing T-cell and B-cell proliferation. Used for Rheumatoid arthritis, Active psoriatic arthritis, Active ankylosing spondylitis.
At a glance
| Generic name | Leflunomide 10 milligram (MG) |
|---|---|
| Sponsor | P. Verschueren |
| Drug class | DHODH inhibitor; disease-modifying antirheumatic drug (DMARD) |
| Target | Dihydroorotate dehydrogenase (DHODH) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Leflunomide's active metabolite, teriflunomide, selectively inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH), which is essential for de novo pyrimidine nucleotide synthesis. This preferentially affects rapidly dividing lymphocytes, which depend heavily on this pathway, leading to reduced T-cell and B-cell proliferation and decreased production of inflammatory cytokines. The drug has both immunosuppressive and anti-inflammatory effects.
Approved indications
- Rheumatoid arthritis
- Active psoriatic arthritis
- Active ankylosing spondylitis
Common side effects
- Diarrhea
- Elevated liver enzymes (ALT/AST)
- Alopecia
- Nausea
- Hypertension
- Respiratory tract infection
- Rash
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leflunomide 10 milligram (MG) CI brief — competitive landscape report
- Leflunomide 10 milligram (MG) updates RSS · CI watch RSS
- P. Verschueren portfolio CI